BioCorRx Inc. (BICX)

[Kizersosae]

This is slide 16 from Biocorrx Investor Presentation published June 2017:

Naltrexone Implant (Biocorrx) Acquired North American rights to new implant formulations and Prodetoxone study data in 2016*

• 3 month formula has been used in other countries as unlicensed product for several years with 6 month version just developed.

• Data acquired for Prodetoxone, which is the ONLY naltrexone implant approved by a regulatory body (Russia for 15+ years)

• Prodetoxone been through multiple trials conducted at St. Petersburg Scientific-Research Center of Addictions and Psychopharmacology, Pavlov Medical University, in conjunction with the University of Pennsylvania, Department of Psychiatry, Philadelphia, USA

• Plans to seek FDA 505(b)(2) regulatory approval in US

*Very similar formulas and protocols were purchased along with the North American rights to certain non-public Prodetoxone study data which is expected to assist in a more efficient FDA approval pathway.

***End Slide***

The more I read the smarter their move sounds. Seems like they got sidetracked with BICX101 and this setback might be a blessing in disguise. In hindsight getting implant approved might be faster to any IND than the path we were on. Next few weeks should be interesting.